New affordable drug for eye conditions caused by diabetes complications 24 July 2015 There is new hope for Australians suffering from diabetes-related eye conditions today following the Federal Government’s announcement that the drug Lucentis would be subsidised under the Pharmaceutical Benefits Scheme (PBS). Diabetes is the leading cause of blindness in working age adults in Australia through eye problems such as diabetic retinopathy and diabetes macular oedema. Minister for Health Sussan Ley today announced that Lucentis, a new drug for the treatment of diabetic macular oedema and retinal vein occlusion, would now be subsidised for patients with a range of serious eye conditions. Lucentis is effective in slowing or stopping the progression of diabetic macular oedema and retinal vein occlusion which are both degenerative conditions that can lead to blindness. Early identification and early treatment is essential to preventing blindness in people with diabetes. Diabetes Australia CEO Professor Greg Johnson welcomed the decision. “Diabetes Australia advocated for listing Lucentis on the PBS on behalf of all Australians with diabetes and their families and carers,†Mr Johnson said. “This listing has the potential to make a real difference to the effective treatment of eye problems for the 1.7 million Australians living with diabetes.†18,000 Australian patients will now pay just $6.10 (concessional) or $37.70 (general) for Lucentis as a result of the expanded listing on the Pharmaceutical Benefits Scheme on 1 July 2015. Diabetes Australia encourages patients to speak to their doctor to see if this medicine is appropriate for them.
Partners 28 November 2023 Dexcom G6 Continuous Glucose Monitoring (CGM) – For people living with Type 1, Type 2 and Gestational Diabetes*Trial now for only $32.10!† Advertisement ALWAYS READ THE LABEL AND FOLLOW THE DIRECTIONS FOR USE. Read the warnings available on dexcom.com/downloadsandguides before purchasing. Consult... Continue Reading
Partners 28 November 2023 Glucose readings every minute for you† and your loved ones* Advertisement The latest version of the FreeStyle LibreLink app† now allows you to receive continuous glucose readings on your phone,... Continue Reading
Media releases 24 November 2023 New vitamin C diabetes research announced Deakin University’s Professor Glenn Wadley is a recipient of one of this year’s Diabetes Australia Research Program (DARP) grants to study the efficacy of vitamin C in the treatment of foot ulcers in people living with diabetes, which can lead to amputations. Continue Reading